

25 μM ATP
100 μM ATP
300 μM ATP
1000 μM ATP
Percent inhibition (±SD)
120
100
80
60
40
20
0
0.001
0.01
0.1
1
10
100
1000
Compound 1 (nM)

FIG. 1



H1299
Percent inhibition (±SEM)
120
100
80
60
40
20
0
-20
IC50 = 1.8 ±0.63 nM
0.1
10
1000
Compound 1 (nM)

FIG. 2



G361
Percent inhibition (±SEM)
120
100
80
60
40
20
0
-20
IC50 = 3.3 ± 3.1 nM
1
10
100
1000
10,000
Compound 1 (nM)

FIG. 3



MAB8912 - + + + + + + + + +
Compound 1 (nM) 0 0 0.1 0.3 1 3 10 30 100 300
pMER
MER

FIG. 4



Percent T-cell Proliferation (± SD)
75
70
65
60
55
50
45
40
0.1
1
10
100
1000
Compound 1 (nM)

FIG. 5A



IFN-γ (mean ± SD, pg/mL)
2500
2000
1500
1000
500
0
DMSO
0.45
1.4
4
12
37
111
333
Compound 1 (nM)

FIG. 5B



IL-2
Expt 1
SEA, Donor A
CD3/CD28, Donor A
SEA, Donor B
CD3/CD28, Donor B
Expt 2
SEA, Donor A
CD3/CD28, Donor A
SEA, Donor B
CD3/CD28, Donor B
3
2
1
Compound 1 (30 nM)
Compound 1 (300 nM)
Retifanlimab
Compound 1 (30 nM) + Retifanlimab
Compound 1 (300 nM) + Retifanlimab

FIG. 6A



IFN-γ
Expt 1
SEA, Donor A
CD3/CD28, Donor A
SEA, Donor B
CD3/CD28, Donor B
Expt 2
SEA, Donor A
CD3/CD28, Donor A
SEA, Donor B
CD3/CD28, Donor B
3
2
1
Compound 1 (30 nM)
Compound 1 (300 nM)
Retifanlimab
Compound 1 (30 nM) + Retifanlimab
Compound 1 (300 nM) + Retifanlimab

FIG. 6B



TFN-α
Expt 1
SEA, Donor A
CD3/CD28, Donor A
SEA, Donor B
CD3/CD28, Donor B
Expt 2
SEA, Donor A
CD3/CD28, Donor A
SEA, Donor B
CD3/CD28, Donor B
1.5
1.0
Compound 1 (30 nM)
Compound 1 (300 nM)
Retifanlimab
Compound 1 (30 nM) + Retifanlimab
Compound 1 (300 nM) + Retifanlimab

FIG. 6C



GM=CSF
Expt 1
SEA, Donor A
CD3/CD28, Donor A
SEA, Donor B
CD3/CD28, Donor B
Expt 2
SEA, Donor A
CD3/CD28, Donor A
SEA, Donor B
CD3/CD28, Donor B
1.5
1.0
Compound 1 (30 nM)
Compound 1 (300 nM) + Retifanlimab
Compound 1 (30 nM) + Retifanlimab
Compound 1 (300 nM) + Retifanlimab

FIG. 6D



IL-12-p70
Expt 1
Expt 2
SEA, Donor A
CD3/CD28, Donor A
SEA, Donor B
CD3/CD28, Donor B
SEA, Donor A
CD3/CD28, Donor A
SEA, Donor B
CD3/CD28, Donor B
Compound 1 (30 nM)
Compound 1 (300 nM)
Retifanlimab
Compound 1 (30 nM) + Retifanlimab
Compound 1 (300 nM) + Retifanlimab
4
3
2
1

FIG. 6E




FIG. 7A




FIG. 7B




FIG. 7D




FIG. 7C




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 9A

FIG. 9B




FIG. 9C



CTG-2041
CTG-1339
Vehicle
Compound 1
Vehicle
Compound 1
pAXL
AXL
pMER
MER
GAS6
pAkt
Akt
Actin

FIG. 9D